Hyderabad based Granules India said the US health regulator has given its approval to the abbreviated new drug application filed by the drug firm for Loratadine tablets used to treat allergies.

“The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India, for Loratadine tablets USP, 10 mg (OTC),” Granules India said in a filing to BSE.’

The approved ANDA is the bioequivalent to the Reference Listed Drug (RLD), Claritin tablets 10 mg by Bayer HealthCare, the filing said. The company further said that commercialisation  of the product is yet to happen.